{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:20:44Z","timestamp":1794561644395,"version":"4.9.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,9]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>The combination of ATRA and ATO, with or without GO, is effective and safe for newly diagnosed APL patients, including the high-risk subset. Long-term follow-up suggests the responses are durable, with very rare relapses.<\/jats:p>","DOI":"10.1182\/blood-2016-09-736686","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T21:31:27Z","timestamp":1482355887000},"page":"1275-1283","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":240,"title":["Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7912","authenticated-orcid":false,"given":"Yasmin","family":"Abaza","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-8077","authenticated-orcid":false,"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California, Irvine, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"McCue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Foudray","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCue","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111902503806800_B1","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2019111902503806800_B2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"issue":"36","key":"2019111902503806800_B3","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1200\/JCO.2006.08.1596","article-title":"Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group","volume":"24","author":"Ad\u00e8s","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111902503806800_B4","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111902503806800_B5","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V82.11.3241.3241","article-title":"Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group","volume":"82","author":"Fenaux","year":"1993","journal-title":"Blood"},{"issue":"8","key":"2019111902503806800_B6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.leu.2401859","article-title":"Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group","volume":"14","author":"Fenaux","year":"2000","journal-title":"Leukemia"},{"issue":"4","key":"2019111902503806800_B7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood"},{"issue":"13","key":"2019111902503806800_B8","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111902503806800_B9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2404006","article-title":"Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy","volume":"20","author":"de Botton","year":"2006","journal-title":"Leukemia"},{"issue":"15","key":"2019111902503806800_B10","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"Shen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111902503806800_B11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3324\/haematol.10541","article-title":"Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML\/RARalpha-positive leukemic stem cells","volume":"92","author":"Zheng","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"2019111902503806800_B12","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/cncr.11314","article-title":"Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience","volume":"97","author":"Lazo","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"2019111902503806800_B13","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"issue":"18","key":"2019111902503806800_B14","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111902503806800_B15","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2003.01.149","article-title":"Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia","volume":"21","author":"Raffoux","year":"2003","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111902503806800_B16","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data","volume":"28","author":"Mathews","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111902503806800_B17","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111902503806800_B18","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2010.32.2107","article-title":"Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia","volume":"29","author":"Ghavamzadeh","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111902503806800_B19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.189.7.1043","article-title":"Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia","volume":"189","author":"Lallemand-Breitenbach","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"2019111902503806800_B20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V97.1.264","article-title":"Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo","volume":"97","author":"Jing","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111902503806800_B21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1521-6926(03)00044-6","article-title":"Treatment of older adults with acute promyelocytic leukaemia","volume":"16","author":"Fenaux","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2019111902503806800_B22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.728","article-title":"An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid","volume":"22","author":"Wang","year":"2004","journal-title":"Hematol Oncol"},{"issue":"2","key":"2019111902503806800_B23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111902503806800_B24","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111902503806800_B25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111902503806800_B26","author":"Iland"},{"issue":"12","key":"2019111902503806800_B27","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/blood.V93.12.4131","article-title":"Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial","volume":"93","author":"Burnett","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2019111902503806800_B28","first-page":"1247","article-title":"Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2019111902503806800_B29","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.leu.2403807","article-title":"Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells","volume":"19","author":"Takeshita","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"2019111902503806800_B30","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"issue":"7","key":"2019111902503806800_B31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111902503806800_B32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.11329","article-title":"Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia","volume":"92","author":"Breccia","year":"2007","journal-title":"Haematologica"},{"issue":"32","key":"2019111902503806800_B33","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: time to resurrect?","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111902503806800_B34","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111902503806800_B35","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019111902503806800_B36","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial [published online ahead of print 11 July 2016]","author":"Platzbecker","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111902503806800_B37","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111902503806800_B38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.leu.2403597","article-title":"Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience","volume":"19","author":"Ades","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"2019111902503806800_B39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.beha.2008.09.002","article-title":"What is the role of arsenic in newly diagnosed APL?","volume":"21","author":"Tallman","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2019111902503806800_B40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00277-002-0534-8","article-title":"Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia","volume":"81","author":"Thomas","year":"2002","journal-title":"Ann Hematol"},{"key":"2019111902503806800_B41","doi-asserted-by":"crossref","article-title":"Therapy-related MDS and AML in acute promyelocytic leukemia","author":"Andersen","DOI":"10.1182\/blood-2002-03-0962"},{"issue":"9","key":"2019111902503806800_B42","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.leu.2402616","article-title":"Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL)","volume":"16","author":"Garcia-Manero","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2019111902503806800_B43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V99.3.822","article-title":"Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem","volume":"99","author":"Latagliata","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111902503806800_B44","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3109\/10428194.2014.953143","article-title":"Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide","volume":"56","author":"Eghtedar","year":"2015","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1275\/1398785\/blood736686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1275\/1398785\/blood736686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:51:38Z","timestamp":1574131898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/10\/1275\/36003\/Longterm-outcome-of-acute-promyelocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-736686","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727137606.793534681","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}